NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Pacira Biosciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024. Follow the link below to get more information and be contacted by a member of our team:

NEW YORK, Jan. 20, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024. A lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 14, 2025.

NEW YORK, Jan. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX).

Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

NEW ORLEANS, Jan. 17, 2025 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until March 14, 2025 to file lead plaintiff applications in a securities class action lawsuit against Pacira BioSciences, Inc. (the "Company") (NasdaqGS: PCRX), if they purchased the Company's securities between August 2, 2023 and August 8, 2024, inclusive (the "Class Period").  This action is pending in the United States District Court for the District of New Jersey.

NEW YORK, Jan. 17, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.

CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024. Follow the link below to get more information and be contacted by a member of our team:

LOS ANGELES, Jan. 17, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ: PCRX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

NEW YORK, Jan. 16, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira BioSciences, Inc. ("Pacira" or "the Company") (NASDAQ: PCRX) and certain of its officers.

Class Definition

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Pacira securities between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/PCRX.

NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX).

Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Pacira To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $75,000 in Pacira between August 2, 2023 and August 8, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Jan. 15, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) and reminds investors of the March 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

NEW YORK, Jan. 15, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024. A lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 14, 2025.

SAN DIEGO, Jan. 14, 2025 /PRNewswire/ -- Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Pacira BioSciences, Inc. (NASDAQ: PCRX) securities between August 2, 2023 and August 8, 2024. Pacira is an American pharmaceutical company committed to developing and providing non-opioid pan management and regenerative health solutions.

Believes Pacira's Cash Balance of $400 million, Roughly 59% of its Market Capitalization, is Grossly Inefficient.

Emphasizes the Current Stock Price Offers an Extraordinary Opportunity to Create Meaningful Return for Shareholders

MIAMI, Sept. 25, 2024 /PRNewswire/ -- DOMA Perpetual Capital Management LLC today sent a letter to the Board of Directors of Pacira Biosciences (NYSE: PCRX) urging the Board to accelerate and increase its stock repurchase.